Vanessa Braunstein
Senior Director, TuneLab AI Drug Discovery Platform Ecosystem Growth Eli Lilly & Co.
Vanessa Braunstein is Senior Director of the TuneLab AI Drug Discovery Platform at Eli Lilly and Company, where she focuses on accelerating early-stage drug discovery through the application of AI and machine learning. With more than two decades of experience across pharmaceuticals, biotechnology, genomics, diagnostics, and healthcare technology, she has held leadership roles at NVIDIA, Oracle, Sanofi, QIAGEN, and other innovative life science organizations. Combining a background in molecular and cell biology with expertise in product development, business strategy, and commercialization, Vanessa is dedicated to advancing AI-enabled solutions that help researchers discover and develop new medicines more efficiently.
Seminars
- Understanding the state-of-play of AI/ML and computational methods across in silico drug design and complementary integration to improve quality and timelines of drug discovery workflows
- Evaluating applications of AI/ML showing promise through experimental validation and dealmaking versus discovery use cases that remain challenging
- Debating global attitudes and the best approaches to foster global discovery collaborations, highlighting the importance of experimental validation and access to quality data resources
- Understanding that AI and ML models require large amounts of data to produce reliable results, often inaccessible to biotech companies
- Laying out the TuneLab toolbox with access to Lilly-trained AI models across biologic modalities to accelerate privacy-preserving drug discovery programs
- Exploring real-world examples of partners leveraging TuneLabs to accelerate internal drug discovery programs
